Cramer's 'Mad Money' Recap: Vision Quest

Click here for an archive of Cramer's "Mad Money" recaps.

---

The Eyes Have It

It's time to buy the greatest medical stock you've never heard, Jim Cramer told his "Mad Money" TV show viewers Thursday, and that stock is OccuLogix(RHEO).

People aren't just paying for vanity as they age, they'd also like to be able to see, Cramer said. But those who suffer from age-related macular degeneration are losing their eyesight.

There are treatments on the market for wet macular degeneration, but there's really nothing out there for dry macular degeneration, which usually comes first.

But OccuLogix has a blood filtration procedure to treat dry macular degeneration, and Cramer said that this could mean mad money.

Cramer said there were no vitamin plays that could offer the kind of returns OccuLogix may someday unleash, but he added that the stock was speculative. So Cramer emphasized that it would be important to use limit orders.

Just Don't Short Us

Back in September Cramer told viewers to buy JDSU(JDSU) at $2; the stock has gained more than 39%.

If Cramer had bought it at that price, he said he'd probably take a little off the top now, because "bulls make money, bears make money, but pigs get slaughtered."

But if you didn't get in then, the stock is still a buy, particularly once the price retreats back to $2.50 from its current $2.79.

Of all the reasons Cramer thinks viewers should own JDSU, he said that positive analyst coverage will unleash some real upside for the stock. Lehman Brothers upgraded the stock, and it rose 12%, he said.

By buying communications test and measurement company Acterna, JDSU has diversified away from a pure telecommunications play and gotten better gross margins, Cramer said. And its optical component business is turning around and is on fire.